Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront

被引：4
|
作者：
Breccia, Massimo [1 ]
Molica, Matteo [1 ]
Colafigli, Gioia [1 ]
Zacheo, Irene [1 ]
Latagliata, Roberto [1 ]
Tafuri, Agostino [2 ,3 ]
Alimena, Giuliana [1 ]
机构：
[1] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, I-00161 Rome, Italy
[2] S Andrea Hosp, Hematol, Rome, Italy
[3] Univ Roma La Sapienza, Dept Mol Med, Hematol, I-00161 Rome, Italy
来源：
LEUKEMIA & LYMPHOMA | 2015年 / 56卷 / 07期
关键词：
D O I：
10.3109/10428194.2014.993391
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2206 / 2207
页数：2
相关论文
共 50 条
  • [1] Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure
    Jabbour, Elias
    Kantarjian, Hagop
    O'Brien, Susan
    Shan, Jenny
    Garcia-Manero, Guillermo
    Wierda, William
    Ravandi, Farhad
    Borthakur, Gautam
    Rios, Mary Beth
    Cortes, Jorge
    BLOOD, 2011, 117 (06) : 1822 - 1827
  • [2] Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia
    Swords R.
    Alvarado Y.
    Cortes J.
    Giles F.J.
    Current Hematologic Malignancy Reports, 2007, 2 (2) : 83 - 88
  • [3] Second generation tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia
    le Coutre, P.
    Baskaynak, G.
    Schwarz, M.
    Petereit, C.
    Westermann, J.
    Dorken, B.
    ANNALS OF ONCOLOGY, 2007, 18 : 17 - 17
  • [4] Improved Drug Adherence in Patients with Chronic Myeloid Leukemia in the Chronic Phase by Switching to Second-Generation Tyrosine Kinase Inhibitors
    Maeda, Yasuhiro
    Okamoto, Atsushi
    Kawaguchi, Shin-ichiro
    Konishi, Akiko
    Yamamoto, Kenta
    Eguchi, Go
    Kanai, Yoshitaka
    Yamaguchi, Terufumi
    ACTA HAEMATOLOGICA, 2017, 138 (03) : 140 - 142
  • [5] Chronic Myeloid Leukemia Therapy: Focus on Second-Generation Tyrosine Kinase Inhibitors
    McFarland, K. Leigh
    Wetzstein, Gene A.
    CANCER CONTROL, 2009, 16 (02) : 132 - 140
  • [6] Outcome of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients Treated with Various Frontline Second-Generation Tyrosine Kinase Inhibitors: A Single-Center Experience
    Lee, Sung-Eun
    Choi, Soo Young
    Kim, Soo-Hyun
    Song, Hye-Young
    Yoo, Hea-Lyun
    Lee, Mi-Young
    Kang, Ki-Hoon
    Hwang, Hee-Jeong
    Jang, Eun-Jung
    Kim, Dong-Wook
    BLOOD, 2015, 126 (23)
  • [7] Impact of Second-Generation Tyrosine Kinase Inhibitors As Second Line Treatment for Patients with Chronic Myeloid Leukemia
    Valentin Garcia-Gutierrez, J.
    Herrera, Pilar
    Abalo, Lorena L.
    Dolores Rey, Maria
    Calbacho, Maria
    Ramos, Lourdes
    Ramos, Paloma
    Montalban, Carlos
    Lopez-Jimenez, Javier
    BLOOD, 2011, 118 (21) : 1615 - 1615
  • [8] Adherence and persistence to second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
    Trivedi, Digisha
    Amin, Shahla
    Zhu, Ling
    Joo, Sam
    Kawabata, Hugh
    Darkow, Theodore
    Hebden, Tony
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] VALIDATION OF A PROGNOSTIC SCORING SYSTEM IN PATIENTS TREATED WITH SECOND-GENERATION TYROSINE KINASE INHIBITORS FOR CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER IMATINIB FAILURE
    Boquimpani, C.
    Schaffel, R.
    Graca, D.
    Mesquita, C.
    Peixoto, D.
    Madeira, T.
    Wendling, P.
    Eller, F.
    Biasoli, I.
    Spector, N.
    HAEMATOLOGICA, 2013, 98 : 553 - 553
  • [10] Second-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia with Additional Chromosomal Abnormalities
    Takahashi, Naoto
    Yoshioka, Tomoko
    Kizaki, Masahiro
    Kawaguchi, Tatsuya
    Suzuki, Ritsuro
    Yamamoto, Kazuhito
    Ohnishi, Kazunori
    Naoe, Tomoki
    Matsumura, Itaru
    BLOOD, 2019, 134
12345